MammaPrint

Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer

Retrieved on: 
Wednesday, March 20, 2024
Biotechnology, FDA, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, IO, Conference, Entrepreneurship, Response, Immunotherapy, Partnership, Risk, Patient, MammaPrint, University, Biology, University of California, Imprint, Genomics, Breast cancer, Medical laboratory, RPS, Pharmaceutical industry

Agendia®, Inc. today announced new data from the I-SPY 2 trial showcasing its ImPrint signature for patients with triple negative (TN) breast cancer, shared by I-SPY 2 researchers in an oral presentation at the 14th European Breast Cancer Conference in Milan, Italy.

Key Points: 
  • Agendia®, Inc. today announced new data from the I-SPY 2 trial showcasing its ImPrint signature for patients with triple negative (TN) breast cancer, shared by I-SPY 2 researchers in an oral presentation at the 14th European Breast Cancer Conference in Milan, Italy.
  • Agendia has been in partnership with Quantum Leap Healthcare Collaborative, the sponsors of the neoadjuvant biomarker-rich I-SPY 2 trial, since 2010.
  • ), investigates the utility of a refined version of ImPrint, called ImPrintTN, designed to provide more accurate predictions to response to common immunotherapy (IO) regimens for TN patients.
  • “Many immunotherapy treatments can have difficult, severe adverse side effects on patients that can outweigh the benefit of the treatment.

Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens

Retrieved on: 
Friday, March 8, 2024
Research, Genetics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Gene expression profiling, Breast cancer, Neoplasm, Taxane, Woman, Transcriptome, MD, MBCC, Cyclophosphamide, Anthracycline, PCR, MammaPrint, Risk, Conference, Symantec Endpoint Protection, AC-T, Patient, MP, Diagnosis, Triple-negative breast cancer, Blueprint, TC, Medical imaging

The first poster, titled MammaPrint® and BluePrint® predict anthracycline chemosensitivity in patients with HR+HER2-early-stage breast cancer enrolled in FLEX, (Audeh, W., et al.

Key Points: 
  • The first poster, titled MammaPrint® and BluePrint® predict anthracycline chemosensitivity in patients with HR+HER2-early-stage breast cancer enrolled in FLEX, (Audeh, W., et al.
  • ), investigates the associations between MammaPrint and BluePrint classifications, therapy regimen, and the likelihood of achieving a pathologic Complete Response (pCR).
  • The second poster, titled Prediction of chemotherapy benefit by MammaPrint® in patients with HR+HER2-early-stage breast cancer from real-world evidence studies (Audeh, W., et al.
  • Taken together, these findings indicate the utility of MammaPrint to predict neoadjuvant and adjuvant chemotherapy benefit in this patient population.

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

Retrieved on: 
Friday, December 1, 2023
BRCA1, HR, PALB2, Magnetic resonance imaging, Nottingham Prognostic Index, Woman, Research, Prevalence, Gene, ICI, Breast cancer, Cancer, DS, Risk, Disease, Epistasis, Patient, Tumor microenvironment, DCIS, Exact sciences, Ductal carcinoma, Gene expression, Genetic testing, Messenger, BRCA2, NPI, HER2, MammaPrint, Oncotype (Denmark), Medicine, Biomarker, ERBB2, Summary, Neoplasm, Recurrence, Clinical, TNBC, Medical imaging, Birth control, Vaccine, MD

"Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients.

Key Points: 
  • "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients.
  • In cooperation with several leading breast cancer research organizations, Exact Sciences will present late-breaking data and a study included in the SABCS press program.
  • Results from Puerto Rico will also detail germline findings for a cohort of women, most of whom had a personal or familial history of breast cancer.
  • Exact Sciences will also host a discussion about the Oncotype DX Breast Recurrence Score test and the RSClin® Tool.

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

Retrieved on: 
Thursday, November 30, 2023
BRCA1, HR, PALB2, Magnetic resonance imaging, Nottingham Prognostic Index, Woman, Research, Prevalence, Gene, ICI, Breast cancer, Cancer, DS, Risk, Disease, Epistasis, Patient, Tumor microenvironment, DCIS, Exact sciences, Ductal carcinoma, Gene expression, Genetic testing, Messenger, BRCA2, NPI, HER2, MammaPrint, Oncotype (Denmark), Medicine, Biomarker, ERBB2, Summary, Neoplasm, Recurrence, Clinical, TNBC, Medical imaging, Birth control, Vaccine, MD

"Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients.

Key Points: 
  • "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients.
  • In cooperation with several leading breast cancer research organizations, Exact Sciences will present late-breaking data and a study included in the SABCS press program.
  • Results from Puerto Rico will also detail germline findings for a cohort of women, most of whom had a personal or familial history of breast cancer.
  • Exact Sciences will also host a discussion about the Oncotype DX Breast Recurrence Score test and the RSClin® Tool.

Agendia® Collaborates with National Cancer Institute, SWOG Cancer Research Network for Phase III Trial; Led by University of Michigan's Dr. Erin Cobain

Retrieved on: 
Tuesday, October 31, 2023
Principal, MP2, Breast, NCI, MP, HER2, MD, PCR, SWOG, Doctor of Philosophy, National Cancer Institute, Clinical trial, Neoplasm, NSC, Breast cancer, Recurrence, Immunotherapy, University, HR, Gene, Wright Axcess-Ultralow, Woman, Cancer, University of Michigan, Patient, Gene expression profiling, Birth control, Pharmaceutical industry, Health, MammaPrint

IRVINE, Calif. and AMSTERDAM, Oct. 31, 2023 /PRNewswire/ -- Agendia, Inc., a global leader in innovative genomic technology and diagnostic tests, is collaborating with National Cancer Institute (NCI), part of the National institutes of Health and SWOG Cancer Research Network, funded by NCI, for a new clinical trial that will test the effectiveness of neoadjuvant immunotherapy for high-risk HR+ breast cancer patients.

Key Points: 
  • SWOG S2206 will use MammaPrint® breast cancer recurrence test to examine response to immunotherapy in women with high-risk HR+ breast cancer.
  • This trial is sponsored by NCI and led by SWOG with participation of the National Clinical Trials Network (NCTN).
  • Dr. Erin Cobain, MD, University of Michigan, will be the Principal Investigator of S2206.
  • Also collaborating on the study is Dr. Lajos Pusztai, MD, PhD, Yale University Cancer Center, who serves as the SWOG Breast Cancer Committee Chair.

Agendia® Names Joyce A. O'Shaughnessy, MD as New Principal Investigator for FLEX Study

Retrieved on: 
Tuesday, October 10, 2023
Diagnosis, Gene expression, Knowledge, Internal medicine, MS, Biology, Research, Breast cancer, School, MD, FLEX, Society, American Society of Clinical Oncology, Radiation, Baylor, American Association for Cancer Research, Science, Natural history, Neoplasm, Woman, Genomics, Joe Byrd (Cherokee Nation Principal Chief), Sarah Cannon Research Institute, Patient, Oncology, Medical imaging, MammaPrint

IRVINE, Calif. and AMSTERDAM, Oct. 10, 2023 /PRNewswire/ -- Agendia®, Inc., a global leader in innovative genomic technology and diagnostic tests, announced today that Dr. Joyce A. O'Shaughnessy, MD has been appointed as the new National Principal Investigator for the FLEX Study, a real-world, large-scale, prospective, observational breast cancer study (NCT03053193) intended to enable the discovery of novel gene expression profiles, through the capture of whole transcriptome and extensive clinical data, to expand knowledge and improve precision in the management of breast cancer.

Key Points: 
  • Dr. O'Shaughnessy is board certified in both internal medicine as well as medical oncology and focuses her practice and clinical research on breast cancer treatment.
  • To date, more than 14,000 patients have been successfully enrolled in the FLEX Study, with representation of various ages, races, ethnicities, and health statuses.
  • "We are honored to have Dr. Joyce O'Shaughnessy join our efforts as the National Principal Investigator for the landmark FLEX Study.
  • For more information about Agendia and the FLEX Study, visit www.agendia.com and follow Agendia on Facebook , Twitter ,  and LinkedIn .

New Neoadjuvant Trial Confirms the Predictive Utility of MammaPrint® + BluePrint®

Retrieved on: 
Thursday, September 28, 2023
Blueprint, Lymphedema, Surgical oncology, Neoadjuvant therapy, NCT, Neoplasm, Cancer, Woman, Breast, Gene expression profiling, MS, MINT, TAD, Annals of Surgical Oncology, MD, Patient, Lymph, Risk, Rollcage Stage II, Health, III, Breast cancer, Medical imaging, MammaPrint

IRVINE, Calif. & AMSTERDAM, Sept. 28, 2023 /PRNewswire/ -- Agendia®, Inc., a global leader in innovative genomic technology and diagnostic tests, announced today the publication of the Multi-Institutional Neoadjuvant Therapy MammaPrint Project I (MINT) trial, a prospective study designed to evaluate the utility of molecular profiling alongside traditional pathologic and clinical prognostic factors in predicting the response to neoadjuvant chemotherapy (NCT) in patients with locally advanced breast cancer (LABC).

Key Points: 
  • This is the first neoadjuvant study to show that nodal downstaging in response to neoadjuvant therapy can be predicted by MammaPrint + BluePrint, Agendia's advanced genomic assays.
  • The MINT trial represents a collaboration of leading institutions and researchers dedicated to advancing breast cancer treatment.
  • It reaffirms the commitment of the scientific and medical communities to improve patient care and outcomes through cutting-edge research.
  • For more information about Agendia, visit www.agendia.com and follow Agendia on Facebook , Twitter ,  and LinkedIn .

Intravacc publishes 2022 annual report

Retrieved on: 
Thursday, June 29, 2023
Cell biology, University, GE HealthCare, Marketing, Bank statement, Infection, COVID, Doctor of Philosophy, Sale, Ministry, VWS, Privatization, Henry Whithed, CDMO, Thermo Fisher Scientific, Dutch States Army, Frida, PDF, Annual report, Pharmaceutical industry, Health, Epigenomics, MammaPrint

BILTHOVEN, Netherlands, June 29, 2023 /PRNewswire/ -- Intravacc B.V., a leading CDMO for infectious diseases and therapeutic vaccines, announced today the publication of its 2022 annual report and the appointment of Frieda Gerdes, PhD as Vice President  Business Development and Marketing.

Key Points: 
  • BILTHOVEN, Netherlands, June 29, 2023 /PRNewswire/ -- Intravacc B.V., a leading CDMO for infectious diseases and therapeutic vaccines, announced today the publication of its 2022 annual report and the appointment of Frieda Gerdes, PhD as Vice President  Business Development and Marketing.
  • The comprehensive annual report for the financial year 2022, encompassing a thorough review of key figures, performance highlights, and financial statements for the period ending on December 31, 2022, is now available online at https://www.intravacc.nl .
  • Intravacc is also pleased to announce the newly appointed Vice President Business Development & Marketing (VP BD&M) Mrs. Frieda Gerdes, PhD.
  • The Dutch State intends to sell 100% of the issued and outstanding shares in Intravacc B.V. through a controlled auction process.

Intravacc publishes 2022 annual report

Retrieved on: 
Thursday, June 29, 2023
Cell biology, University, GE HealthCare, Marketing, Bank statement, Infection, COVID, Doctor of Philosophy, Sale, Ministry, VWS, Privatization, Henry Whithed, CDMO, Thermo Fisher Scientific, Dutch States Army, Frida, PDF, Annual report, Pharmaceutical industry, Health, Epigenomics, MammaPrint

BILTHOVEN, Netherlands, June 29, 2023 /PRNewswire/ -- Intravacc B.V., a leading CDMO for infectious diseases and therapeutic vaccines, announced today the publication of its 2022 annual report and the appointment of Frieda Gerdes, PhD as Vice President  Business Development and Marketing.

Key Points: 
  • BILTHOVEN, Netherlands, June 29, 2023 /PRNewswire/ -- Intravacc B.V., a leading CDMO for infectious diseases and therapeutic vaccines, announced today the publication of its 2022 annual report and the appointment of Frieda Gerdes, PhD as Vice President  Business Development and Marketing.
  • The comprehensive annual report for the financial year 2022, encompassing a thorough review of key figures, performance highlights, and financial statements for the period ending on December 31, 2022, is now available online at https://www.intravacc.nl .
  • Intravacc is also pleased to announce the newly appointed Vice President Business Development & Marketing (VP BD&M) Mrs. Frieda Gerdes, PhD.
  • The Dutch State intends to sell 100% of the issued and outstanding shares in Intravacc B.V. through a controlled auction process.

Agendia Appoints Ronald Andrews and David Schreiber to Board of Directors

Retrieved on: 
Wednesday, June 14, 2023
Biotechnology, Health, Genetics, Health Technology, Oncology, Heart, Quest Diagnostics, GE HealthCare, American Society of Clinical Oncology, Council for Responsible Genetics, Woman, Life Technologies, Breast, Labcorp, MBA, Thermo Fisher Scientific, Research, Gene expression profiling, ASCO, Ron, Sale, University of Illinois Urbana-Champaign, Patient, Physician, Northern Illinois University, Wofford College, CFO, Roche, Society, Breast cancer, Management, Nursing, Science, Biology, Oncocyte, MammaPrint

Agendia, Inc. , a gene expression profiling company advancing personalized early-stage breast cancer care, today announced the appointment of industry veterans Ronald (Ron) Andrews and David Schreiber to the company’s Board of Directors.

Key Points: 
  • Agendia, Inc. , a gene expression profiling company advancing personalized early-stage breast cancer care, today announced the appointment of industry veterans Ronald (Ron) Andrews and David Schreiber to the company’s Board of Directors.
  • Patrick Balthrop, Chair of the Agendia Supervisory Board, said, “On behalf of the Agendia Supervisory Board, all of our stakeholders and most importantly, the breast cancer patients that we serve, I welcome Ron and David to the company and to the Board.
  • Most recently, he served as a Board Member and as the President and Chief Executive Officer of Oncocyte.
  • “I look forward to working with the Board and the Agendia team to make a difference for patients with breast cancer.”
    Mr. Schreiber brings nearly 40 years of experience in the laboratory diagnostics space to his Board seat at Agendia.